Usefulness of prolactin levels in predicting the etiology of hyperprolactinemia in a cohort of 770 patients.


Journal

Archives of endocrinology and metabolism
ISSN: 2359-4292
Titre abrégé: Arch Endocrinol Metab
Pays: Brazil
ID NLM: 101652058

Informations de publication

Date de publication:
2024
Historique:
received: 12 12 2023
accepted: 04 04 2024
medline: 18 10 2024
pubmed: 18 10 2024
entrez: 18 10 2024
Statut: epublish

Résumé

Determining the etiology of hyperprolactinemia is fundamental for selecting the most appropriate treatment strategy. The aim of this study was to evaluate the usefulness and accuracy of prolactin levels in predicting the etiology of nonphysiological hyperprolactinemia. In this retrospective study, we reviewed medical records of patients with nonphysiological hyperprolactinemia seen at two neuroendocrine reference centers located in Recife, Brazil, from January 2000 to December 2019. The study included 770 patients aged 12-73 years (65% female). The three most frequent etiologies of hyperprolactinemia were prolactinomas (n = 263; 34.2%), drug-induced hyperprolactinemia (n = 160; 20.8%), and macroprolactinemia (n = 120; 15.6%). The highest mean prolactin levels were observed in cases of prolactinomas and idiopathic hyperprolactinemia. Most patients with hyperprolactinemia due to other etiologies had prolactin levels < 100 ng/mL, but these levels were also found in 16.5% of patients with microproplactinomas and in 20% of those with idiopathic hyperprolactinemia. Likewise, prolactin levels largely overlapped among patients with microprolactinomas, macroprolactinemia, and drug-induced hyperprolactinemia. Notably, prolactin levels > 250 ng/mL enabled a clear distinction between the etiologies of macroprolactinoma and nonfunctioning pituitary adenoma. Moreover, prolactin levels > 500 ng/mL were highly suggestive of macroprolactinomas, although they were also found in very few patients (<2%) with microprolactinomas or drug-induced hyperprolactinemia. Despite considerable overlap in prolactin levels among the different etiologies of hyperprolactinemia, values > 250 ng/mL allowed a clear distinction between macroprolactinomas and nonfunctioning pituitary adenomas. Furthermore, prolactin levels > 500 ng/mL were almost exclusively found in patients with prolactinomas.

Identifiants

pubmed: 39420933
doi: 10.20945/2359-4292-2023-0391
pmc: PMC11460971
doi:

Substances chimiques

Prolactin 9002-62-4
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e230391

Déclaration de conflit d'intérêts

Disclosure: no potential conflict of interest relevant to this article was reported.

Auteurs

Lucio Vilar (L)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.
Centro de Pesquisas Endócrinas de Pernambuco RecifePE Brasil Centro de Pesquisas Endócrinas de Pernambuco, Recife, PE, Brasil.

Clarice Freitas Vilar (CF)

Centro de Pesquisas Endócrinas de Pernambuco RecifePE Brasil Centro de Pesquisas Endócrinas de Pernambuco, Recife, PE, Brasil.

Ruy Lyra (R)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Luciano Albuquerque (L)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Ana Carolina Thé Garrido (ACT)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Patrícia Sampaio Gadelha (PS)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Erik Trovão Diniz (ET)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Marcos Almeida (M)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Lucia Helena Cordeiro (LH)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Erico Higino de Carvalho (EH)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Ana Teresa Bezerra de Melo (ATB)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Karoline Matias Medeiros (KM)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Gabriel Rodrigues de Assis Ferreira (GRA)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

José Coelho Mororó (JC)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Daniela Zago Ximenes (DZ)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Camila Ribeiro Coutinho Madruga (CRC)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Rosália de Oliveira Nunes (RO)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Yanna Queiroz Pereira de Sá (YQP)

Divisão de Endocrinologia Hospital das Clínicas Universidade Federal de Pernambuco RecifePE Brasil Divisão de Endocrinologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil.

Luciana Ansaneli Naves (LA)

Divisão de Endocrinologia Hospital Universitário de Brasília BrasíliaDF Brasil Divisão de Endocrinologia, Hospital Universitário de Brasília, Brasília, DF, Brasil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH